Muscular Dystrophy Therapy by Increased Angiogenesis
Muscular Dystrophy Therapy by Increased Angiogenesis
批准号:
8366037
负责人:
ATSUSHI ASAKURA
金额:
$7.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2015-07-31
关键词:
AddressAdultAffectAngiogenic FactorBindingBlood VesselsBlood flowCell Membrane PermeabilityClinicalConnective TissueDataDiseaseDuchenne muscular dystrophyDystrophinDystrophin-Associated Protein ComplexEmbryoEndothelial CellsFibrosisGene DeletionGene ExpressionGenesGoalsHistologyHistopathologyHousingHumanInjection of therapeutic agentIntramuscular InjectionsIntraperitoneal InjectionsKnowledgeLaboratoriesLeadLinkMembraneModelingMusMuscleMuscle FibersMuscle functionMuscle satellite cellMuscular DystrophiesMutant Strains MiceMyopathyNatural regenerationNeuromuscular DiseasesNewborn InfantPathologyPatientsPeptidesPhenotypeProductionProteinsPublicationsRegulationReportingResearchSkeletal MuscleSurvival RateTestingUtrophinVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth FactorsVascular Smooth MuscleVascular blood supplyWorkabstractingangiogenesisbasecalcificationdensitygene therapyimprovedknockout genemalemdx mousemuscle regenerationmuscular dystrophy mouse modelmutantnovelreceptorrepairedsatellite cellsmall hairpin RNA
中文摘要
描述(由申请人提供):项目摘要/摘要杜氏肌营养不良症(DMD)是一种进行性疾病,其中肌营养不良蛋白的缺失导致肌膜上肌营养不良蛋白桥的缺失。最近的工作表明,肌营养不良蛋白参与血液流动调节,这是在DMD干扰,并导致增加肌肉损伤。然而,血管生成在DMD治疗中的重要性尚未得到很好的解决。我们建议,管理促血管生成因子可以恢复肌肉纤维和血管。为了揭示神经肌肉疾病和血管生成之间的关系,我们最近创建了Flt-1杂合mdx小鼠(mdx:Flt- 1+/-)。mdx小鼠用作DMD的模型,并且血管内皮生长因子(VEGF)与Flt-1受体结合以负调节血管生成。最近,我们的工作揭示了mdx:Flt-1+/-小鼠除了改善的肌肉病理和功能之外还显示出血管数量增加(Verma等人,2010年)。Utrophin缺陷型mdx小鼠(mdx:utrn-/-)显示出比mdx小鼠更严重的表型,并且mdx:utrn-/-小鼠更接近于人DMD表型。重要的是,与mdx:utrn-/-:Flt-1 +/+小鼠相比,mdx:utrn-/-:Flt-1+/-三重突变小鼠显示出改善的肌肉组织学和显著更高的存活率。我们的项目将建立在这些初步数据的基础上,以更密切地揭示血管生成增加最终如何影响mdx小鼠的DMD表型。此外,我们将检查通过给予阻断Flt-1功能的抗Flt-1肽或Flt-1 shRNA提供的血管系统增加是否可以改善mdx和mdx:utrn-/-小鼠的肌肉萎缩表型。
公共卫生相关性:杜氏肌营养不良症(DMD)是由肌营养不良蛋白基因突变引起的,该基因通常用于维持肌肉膜的完整性并防止收缩引起的损伤。通过使用促血管生成因子增加血管数量并观察对肌营养不良表型的影响,可能减少肌纤维损伤。我们预测,这些促血管生成因子将有助于通过增加血液饥饿营养不良肌肉中的血管密度来开发DMD的新疗法。
英文摘要
DESCRIPTION (provided by applicant): Project Summary/Abstract Duchenne Muscular Dystrophy (DMD) is a progressive disorder in which the absence of the dystrophin protein results in loss of the dystrophin bridge at the muscle membrane. Recent work demonstrates the involvement of dystrophin in blood flow regulation, which is disturbed in DMD and causes increased muscle damage. However, the importance of angiogenesis in DMD treatment has not yet been well addressed. We propose that administration of pro-angiogenic factors can restore muscle fibers and blood vessels. To reveal the relationship between neuromuscular disease and angiogenesis, we recently created Flt-1 heterozygous mdx mice (mdx:Flt- 1+/-). mdx mice serve as a model for DMD, and vascular endothelial growth factor (VEGF) binds with Flt-1 receptors to negatively regulate angiogenesis. Recently, our work revealed that the mdx:Flt-1+/- mice display an increased number of blood vessels in addition to improved muscle pathology and function (Verma et al., 2010). Utrophin deficient mdx mice (mdx:utrn-/-) display a more severe phenotype than mdx mice, and the mdx:utrn-/- mice more closely resemble a human DMD phenotype. Importantly, mdx:utrn-/-:Flt-1+/- triple mutant mice display improved muscle histology and significantly higher survival rates compared to mdx:utrn-/-:Flt-1+/+ mice. Our project will build on these preliminary data to more closely reveal how increased angiogenesis ultimately affects the DMD phenotype in mdx mice. In addition, we will examine whether increased vasculature provided by the administration of an anti-Flt-1 peptide or shRNA for Flt-1 that block Flt-1 function can improve the muscular dystrophic phenotype in mdx and mdx:utrn-/- mice.
PUBLIC HEALTH RELEVANCE: Project Narrative Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene, which normally functions to maintain muscle membrane integrity and prevent contraction-induced damage. It may be possible to reduce muscle fiber damage by using pro-angiogenic factors to increase the number of blood vessels and observe the resultant effects on the muscular dystrophy phenotype. We predict that these pro-angiogenic factors will assist development of new therapies for DMD via increased vascular density in blood starved dystrophic muscles.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Systemic delivery of muscle stem cell for muscle disease therapy
-
批准号:10451411
-
项目类别:
-
资助金额:$20.46万
-
财政年份:2022
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Systemic delivery of muscle stem cell for muscle disease therapy
-
批准号:10615789
-
项目类别:
-
资助金额:$17.05万
-
财政年份:2022
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Targeting vascular endothelium for muscular dystrophy therapy
-
批准号:10379330
-
项目类别:
-
资助金额:$16.88万
-
财政年份:2021
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Engineering iPSC-Derived Skeletal Muscle and Cells for Transplantation
-
批准号:9164844
-
项目类别:
-
资助金额:$20.14万
-
财政年份:2016
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Muscular Dystrophy Therapy by Increased Angiogenesis
-
批准号:8729809
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Genetically Engineered Muscle Stem Cell Transplantation for Muscular Dystrophy...
-
批准号:8904607
-
项目类别:
-
资助金额:$33.29万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Genetically Engineered Muscle Stem Cell Transplantation for Muscular Dystrophy...
-
批准号:8729564
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Genetically Engineered Muscle Stem Cell Transplantation for Muscular Dystrophy...
-
批准号:8371147
-
项目类别:
-
资助金额:$32.28万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Genetically Engineered Muscle Stem Cell Transplantation for Muscular Dystrophy...
-
批准号:9116766
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Genetically Engineered Muscle Stem Cell Transplantation for Muscular Dystrophy...
-
批准号:8507146
-
项目类别:
-
资助金额:$31.27万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
Muscular Dystrophy Therapy by Increased Angiogenesis
-
批准号:8507145
-
项目类别:
-
资助金额:$7.17万
-
财政年份:2012
-
负责人:ATSUSHI ASAKURA
-
依托单位:
海外基金